Acuta Capital Partners, LLC Allakos Inc. Transaction History

Acuta Capital Partners, LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$3.02 - $6.12 $581,350 - $1.18 Million	192,500 New	192,500 $1.18 Million
Q4 2021 Feb 14, 2022	SELL	$8.55 - $111.89 $149,625 - $1.96 Million	-17,500 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$76.53 - $110.43 $1.34 Million - $1.93 Million	17,500 New	17,500 $1.85 Million
Q2 2019 Aug 14, 2019	SELL	$36.0 - $44.73 $486,000 - $603,855	-13,500 Closed	0 $0
Q1 2019 May 14, 2019	BUY	$33.79 - $51.99 $456,165 - $701,865	13,500 New	13,500 $547,000

64.7M

47.1K

Ticker ALLK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,726,096
Market Cap $89.8M
Description
Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and...

Get notified when there are updates to the investment portfolio of Acuta Capital Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Acuta Capital Partners, LLC with notifications on news.